紀要論文 過活動膀胱を有する前立腺肥大症患者に対する薬物治療の臨床的検討 : クロスオーバー法を用いた比較検討
A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin

宇都宮, 紀明  ,  松本, 敬優  ,  常森, 寛行  ,  六車, 光英  ,  川喜田, 睦司  ,  上山, 裕樹  ,  金丸, 聰淳  ,  伊藤, 哲之  ,  塚崎, 秀樹  ,  白波瀬, 敏明  ,  高橋, 毅

62 ( 7 )  , pp.341 - 347 , 2016-07-31 , 泌尿器科紀要刊行会
ISSN:0018-1994
NII書誌ID(NCID):AN00208315
内容記述
We compared the efficacy of naftopidil monotherapy with combination therapy using tamsulosin hydrochloride and solifenacin succinate in the treatment of lower urinary tract symptoms (LUTS) with overactive bladder (OAB) secondary to benign prostatic hyperplasia (BPH). Thirty one patients were enrolled in a randomized crossover study. Fourteen patients were initially prescribed naftopidil 75 mg (N) for 8 weeks, followed by tamsulosin 0.2 mg and solifenacin 5 mg (TS) for 8 weeks (group N) ; another 17 were initially prescribed TS, followed by N (group TS). The efficacy variables were the changes in international prostate symptom score (I-PSS), quality of life (QOL) score, overative bladder symptom score (OABSS), and post-void residual (PVR) urine volume. After the study, a questionnaire survey was carried out about the choice of treatment. After treatment with each agent, total I-PSS, storage symptom score, QOL score and OABSS except for the daytime frequency were significantly improved from baseline. PVR was significantly increased after TS treatment. There were no significant differences between the two treatments except for PVR. As a result of the questionnaire survey, 13 patients chose N and 17 chose TS. In conclusion, N monotherapy can be expected to have an equal effect in the treatment of LUTS with OAB secondary to BPH in comparison with TS combination therapy.
本文を読む

http://repository.kulib.kyoto-u.ac.jp/dspace/bitstream/2433/216315/1/62_7_341.pdf

このアイテムのアクセス数:  回

その他の情報